Council Calls for Sharper Price Reductions for Long-Listed Drugs, Increase in Operating Profit Rate When Using Cost Calculation Method

Chairman Motoyuki Oka, Regulatory Reform Council The government’s Regulatory Reform Council (chairman: Motoyuki Oka, senior advisor, Sumitomo Corporation) finalized a proposal on new rules for pricing pharmaceuticals and medical devices at a meeting on August 22. The council would like...read more